RPHM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPHM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2024-06-05), the stock price of Reneo Pharmaceuticals is $1.66. Reneo Pharmaceuticals's graham number for the quarter that ended in Mar. 2024 was $N/A. Therefore, Reneo Pharmaceuticals's Price to Graham Number ratio for today is N/A.
The historical rank and industry rank for Reneo Pharmaceuticals's Graham Number or its related term are showing as below:
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
The historical data trend for Reneo Pharmaceuticals's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reneo Pharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Graham Number | - | - | - | - | - |
Reneo Pharmaceuticals Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Graham Number | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Reneo Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Reneo Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Reneo Pharmaceuticals's Price-to-Graham-Number falls into.
Graham Number is a concept based on Ben Graham's conservative valuation of companies.
Reneo Pharmaceuticals's Graham Number for the fiscal year that ended in Dec. 2023 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI) |
= | sqrt of (22.5 | * | 2.651 | * | -2.52) |
= | N/A |
Reneo Pharmaceuticals's Graham Number for the quarter that ended in Mar. 2024 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI (TTM)) |
= | sqrt of (22.5 | * | 2.431 | * | -2.18) |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reneo Pharmaceuticals (NAS:RPHM) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Reneo Pharmaceuticals's Price to Graham number Ratio for today is calculated as
Price to Graham number | = | Share Price (Today) | / | Graham number (Q: Mar. 2024 ) |
= | 1.66 | / | N/A | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.
Ashley Hall | officer: Chief Development Officer | C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Niall O'donnell | director | C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105 |
Michael Cruse | officer: Senior VP, Corporate Operation | C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Jennifer Lam | officer: VP of Finance & Administration | C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612 |
Paul W. Hoelscher | director | 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015 |
Vineet R. Jindal | officer: Chief Financial Officer | C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130 |
Gregory J. Flesher | director, officer: President and CEO | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Bali Muralidhar | director | C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077 |
Wendy S. Johnson | officer: Chief Development Officer | 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Rivervest Venture Fund Iii (ohio), L.p. | 10 percent owner | 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502 |
Rivervest Venture Fund Iii, L.p. | 10 percent owner | 7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105 |
Stacey Denenberg Seltzer | director | C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
From GuruFocus
By Don Li2 Don Li2 • 11-01-2021
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 03-07-2022
By GuruFocus Research • 11-13-2023
By PurpleRose PurpleRose • 08-02-2022
By Ds*** Ds*** • 08-29-2022
By GuruFocusNews GuruFocusNews • 01-24-2022
By Marketwired • 10-06-2023
By Value_Insider Value_Insider • 11-03-2022
By sperokesalga sperokesalga • 05-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.